Jin Yang Pharmaceutical Co., Ltd.

KOSDAQ:A007370 Rapporto sulle azioni

Cap. di mercato: ₩67.1b

Jin Yang Pharmaceutical Performance dei guadagni passati

Il passato criteri di controllo 5/6

Jin Yang Pharmaceutical ha registrato una crescita degli utili a un tasso medio annuo di 36.5%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 7.8%. I ricavi sono stati in crescita a un tasso medio annuo di 18.6%. Il ritorno sul capitale proprio di Jin Yang Pharmaceutical è 23.8% e ha margini netti di 25.3%.

Informazioni chiave

36.5%

Tasso di crescita degli utili

37.3%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore11.3%
Tasso di crescita dei ricavi18.6%
Rendimento del capitale proprio23.8%
Margine netto25.3%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Nov 22
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

May 23
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

Recent updates

Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Nov 22
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

Aug 19
Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Aug 12
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

May 23
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Mar 22
A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

Mar 04
Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Feb 11
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Jan 21
Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

Jan 04
Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Dec 17
We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Nov 30
Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Ripartizione dei ricavi e delle spese

Come Jin Yang Pharmaceutical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

KOSDAQ:A007370 Ricavi, spese e utili (KRW Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 24111,14928,13260,0810
30 Jun 24103,6019,80756,4990
31 Mar 2499,16811,76653,1480
31 Dec 2394,11112,65947,8510
30 Sep 2387,80612,95141,9460
30 Jun 2385,54615,21939,1010
31 Mar 2380,97313,35236,3200
31 Dec 2276,26412,30834,0310
30 Sep 2274,99112,23431,8020
30 Jun 2268,7828,12429,0940
31 Mar 2266,7468,83927,5580
31 Dec 2162,8399,53826,5830
30 Sep 2158,68011,01624,2120
30 Jun 2154,92710,27022,3090
31 Mar 2151,0997,30721,9590
31 Dec 2049,5255,22921,6470
30 Sep 2049,7862,46524,0190
30 Jun 2048,19792624,4310
31 Mar 2047,87971824,4130
31 Dec 1947,3511,64723,9450
30 Sep 1947,6911,35423,9430
30 Jun 1948,9032,04224,4600
31 Mar 1947,5772,11923,7500
31 Dec 1846,86393323,9910
30 Sep 1844,319-5,35328,8120
30 Jun 1843,858-5,34927,9670
31 Mar 1843,815-5,72428,2570
31 Dec 1743,450-5,76827,8540
30 Sep 1742,432-6,37229,1730
30 Jun 1740,902-7,05428,7850
31 Mar 1740,833-7,24228,1540
31 Dec 1636,132-9,09926,9860
30 Sep 1636,191-3,67421,0950
30 Jun 1635,729-3,53821,7240
31 Mar 1635,400-3,94822,5730
31 Dec 1540,149-1,00423,0740
30 Sep 1544,3883,05821,9230
30 Jun 1546,2463,31122,7780
31 Mar 1546,6904,09922,3900
31 Dec 1445,2374,01321,6360
30 Sep 1444,4284,33319,9240
30 Jun 1443,3795,50118,6670
31 Mar 1440,4584,72718,5190
31 Dec 1340,2354,19318,9490

Guadagni di qualità: A007370 ha un livello elevato di guadagni non monetari.

Margine di profitto in crescita: Gli attuali margini di profitto netti di A007370 (25.3%) A007370 sono più alti rispetto allo scorso anno (14.8%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di A007370 sono cresciuti in modo significativo del 36.5% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di A007370 nell'ultimo anno ( 117.2% ) supera la media quinquennale ( 36.5% all'anno).

Guadagni vs Settore: La crescita degli utili A007370 nell'ultimo anno ( 117.2% ) ha superato la percentuale del settore Pharmaceuticals 22%.


Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 23.8% ) di A007370 è considerato alto.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate